Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East
22 déc. 2021 08h00 HE
|
Vector Pharma FZCO
DUBAI, United Arab Emirates, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Vector Pharma FZCO announced today the signing of an exclusive distribution agreement with R-PHARM US of Princeton, NJ . Under the...
CORRECTING AND REPLACING - LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 déc. 2021 10h06 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please note the date in the first paragraph...
LAVA Therapeutics to Present Corporate Overview at 40th Annual J.P. Morgan Healthcare Conference
20 déc. 2021 07h00 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Dec. 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
Bayhealth Collaborates with Syapse, Bringing Data-Driven Approach to Oncology Care
15 déc. 2021 10h00 HE
|
Syapse
SAN FRANCISCO and DOVER, Del., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing...
Florida Cancer Specialists & Research Institute Celebrates Opening of New State-of-the-Art Cancer Center in Bradenton
18 nov. 2021 17h17 HE
|
Florida Cancer Specialists & Research Institute
Bradenton, Fla, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) held a ribbon-cutting ceremony Wednesday, to mark the opening of its new state-of-the-art...
LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results
15 nov. 2021 07h00 HE
|
LAVA Therapeutics N.V.
LAVA-051 Phase 1/2a trial actively enrolling in hematological malignancies on track to report initial data in H1 2022LAVA-1207 Phase 1/2a trial in metastatic castrate resistant prostate cancer on...
LAVA Therapeutics and The Antibody Society Present Emerging Cancer Therapies Virtual Symposium
11 nov. 2021 10h08 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA and FRAMINGHAM, Mass., Nov. 11, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that...
LAVA Therapeutics Expands Management Team with Three Key Appointments
09 nov. 2021 06h30 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
LAVA Therapeutics to Participate in the 12th Annual Jefferies London Healthcare Conference
04 nov. 2021 07h00 HE
|
LAVA Therapeutics N.V.
UTRECHT, The Netherlands and PHILADELPHIA, Nov. 04, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary...
Stingthera, Inc. Announces Clinical Collaboration with Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
03 nov. 2021 06h45 HE
|
Stingthera, Inc.
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Stingthera, Inc. today announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada)...